Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3

Cancer Biology and Therapy

Volumn 6, Issue 2, 2007, Pages 202-208

  Su, Yue ^a   Zhu, Huabin ^a   Xiao, Wei ^a   Xu, Qin ^a   Zhu, Lei ^a   Zhang, Xianrong ^a   Wan, Qinwen ^a   Zhou, Shumin ^a   Du, Enqi ^a   Xu, Hua ^a   Yao, Lunguang ^a   Lv, Songya ^a   Hu, Baoli ^a   Liu, Yingle ^a   Qi, Yipeng ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Herpes simplex virus type 1; Interaction; mtHSV; Oncolytic mechanism; Ras; Reticulon 3(RTN3); siRNA

Indexed keywords

BETA GALACTOSIDASE; PLASMA PROTEIN; PROTEIN RETICULON 3; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; GENE INSERTION; HELA CELL; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

EID: 34247328617     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.2.3628     Document Type: Article

References (29)

1. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252:854-6.
2. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefield XO. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 1997; 8:2057-68.
3. Boviatsis EJ, Scharf JM, Chase M, Harrington K, Kowall NW, Breakefield XO, Chiocca EA. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase. Gene Ther 1994; 1:323-31.
4. Carroll NM, Chiocca EA, Takahashi K, Tanabe KK. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann Surg 1996; 224:323-9.
5. Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995; 1:938-43.
6. Farassati F, Yang AD, Lee PW. Oncogenes in Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001; 3:745-50.
7. Hancock JF. Ras proteins: Different signals from different locations. Nat Rev Mol Cell Biol 2003; 4:373-84, (Review).
8. Chiu VK, Bivona T, Hatch A, Sajous JB, Silletti J, Wiener HH, Johnson IInd RL, Cox AD, Philips MR. Ras signaling on the endoplasmic reticulum and the Golgi. Nat Cell Biol 2002; 4:343-50.
9. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, Philips MR. Endomembrane trafficking of Ras: The CAAX motif targets proteins to the ER and Golgi. Cell 1999; 98:69-80.
10. Prior IA, Hancock JF. Compartmentalization of Ras proteins. J Cell Sci 2001; 114:1603-8.
11. Omer CA, Kral AM, Diehl RE, Prendergast GC, Powers S, Allen CM, Gibbs JB, Kohl NE. Characterization of recombinant human farnesyl-protein transferase: Cloning, expression, farnesyl diphosphate binding, and functional homology with yeast prenyl-protein transferases. Biochemistry 1993; 32:5167-76.
12. Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993; 260:1934-7.
13. Ochiai N, Uchida R, Fuchida S, Okano A, Okamoto M, Ashihara E, Inaba T, Fujita N, Matsubara H, Shimazaki C. Effect of farnesyl transferase inhibitor R115777 on the growth of fresh and cloned myeloma cells in vitro. Blood 2003; 102:3349-53.
14. Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase. J Cell Biochem Suppl 1997; 27:12-9.
15. Ohkanda J, Knowles DB, Blaskovich MA, Sebti SM, Hamilton AD. Inhibitors of protein farnesyltransferase as novel anticancer agents. Curr Top Med Chem 2002; 2:303-23.
16. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Research 2005; 65:3671-81.
17. Gedhing MJ, Sambrook J. Protein folding in the cell. Nature 1992; 355:33-4533.
18. Boyce M, Bryant KF, Jousse C, Long K, Harding HP, Scheuner D, Kaufman RJ, Ma D, Coen DM, Ron D, Yuan J. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005; 307:935-9.
19. Cheng G, Feng Z, He B. Herpes simplex virus 1 infection activates the endoplasmic reticulum resident kinase PERK and mediates eIF-2alpha dephosphorylation by the gamma(1)34.5 protein. J Virol 2005; 79:1379-88.
20. 2+ depletion triggers apoptotic signals for endoplasmic reticulum (ER) overload response induced by overexpressed reticulon 3 (RTN3/HAP). J Cell Physiol 2005; 204:549-59.
21. Qi B, Qi Y, Watari A, Yoshioka N, Inoue H, Minemoto Y, Yamashita K, Sasagawa T, Yutsudo M. Pro-apoptotic ASY/Nogo-B protein associates with ASYIP. J Cell Physiol 2003; 196:312-8.
22. Feng Xue, Chang-yuan Dong, Yue Su Hua-bing Zhu, Weifang-Ling, Yingle Liu, Hua Xu, Wei Xiao, Shumin-ZhuYi-peng Qi. Tumor-targeted therapy with a conditionally replicating mutant of HSV-1 induces regression of xenografted human hepatomas. Cancer Biol Ther 2005; 4:1234-9.
23. Valdivia RH, Baggott D, Chuang JS, Schekman RW. The yeast clathrin adaptor protein complex 1 is required for the efficient retentionof a subset of late Golgi membrane proteins. Dev Cell 2002; 2:283-94.
24. Bartells DJ, Mitchell DA, Dong X, Deschenes RJ. Erf2, a novel gene product that affects the localization and palmitoylation of Ras2 in Saccharomyces cerevisiae. Mol Cell Biol 1999; 19:6775-87.
25. Chen MS, Huber AB, van der Haar ME, Frank M, Schnell L, Spillmann AA, Christ F, Schwab ME. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000; 403:434-9.
26. Li Q, Qi B, OKa K, Shimakage M, Yoshioka N, Inoue H, Hakura A, Kodama K, Stanbridge EJ, Yutsudo M. Link of a new type of apoptosis-inducing gene Asy/Nogo-B to human cancer. Oncogene 2001; 20:3929-36.
27. Silvius JR. Mechanisms of Ras protein targeting in mammalian cells. J Member Biol 2002; 190:83-92.
28. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: An overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63:5656-68.
29. * Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J Clin Oncol 2006; 24:3013-8.